Structure Therapeutics said Monday that its investigational GLP-1 pill led to substantial weight loss in two mid-stage trials, but patients also experienced high rates of nausea and vomiting.
In the first trial, a 120-mg dose of the drug, a small molecule called aleniglipron, led patients to lose 12.1% of their weight at 36 weeks, while those on placebo lost 0.8%. As for side effects, 65% of treated patients experienced nausea, 32% experienced vomiting, and 11% discontinued due to adverse events.
In the second trial, which is ongoing, patients were first titrated up to 120 mg and then brought to higher doses up to 240 mg. At 36 weeks, patients who ended up on a 240 mg dose lost 14.2% of their weight, while those on placebo gained 1%.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.